Jaundice Clinical Trial
Official title:
Effectiveness of Perioperative Symbiotic Therapy to Reduce Infectious Morbidity in Jaundiced Patients: a Randomized Controlled Trial
The aim of the present study was therefore to evaluate if the perioperative administration of symbiotics reduces postoperative infectious morbidity in jaundiced patients scheduled for hepato-biliary and pancreatic surgery.
Despite advances in preoperative patient's selection and anesthetic and surgical techniques,
surgery in jaundiced patients is associated with significant morbidity and mortality as a
consequence of septic complications. The evidence that nosocomial infections are frequently
a consequence of gut-derived organism such as enterobacteriaceae, supports the hypothesis of
the "gut derived sepsis". Indeed, several studies have reported that jaundiced patients
present an increased intestinal permeability and consequently a higher rate of bacterial
migration from gastrointestinal tract across the lamina propria to local mesenteric lymph
nodes and from there to extra-intestinal site. This phenomenon increases after surgical
decompression of bile duct. The higher prevalence of bacterial translocation in jaundiced
patients is related to different mechanisms such as mucosal atrophy secondary to protracted
absence of intraluminal bile that open para-cellular route for bacterial translocation and
the decreased clearance capacity of Kuppfer secondary to cholestasis.
The mechanisms of action of symbiotics are largely unknown. The probiotic bacteria can
improve the mucosal barrier function reducing the bacterial translocation of organism to
mesenteric lymph nodes. Indeed symbiotic can affect the intestinal ecosystem by stimulating
mucosal immune and non-immune mechanisms through antagonism/competition with potential
pathogens.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00360204 -
Improving Health Outcomes for New Mothers and Babies
|
Phase 3 | |
Completed |
NCT00383318 -
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia
|
N/A | |
Withdrawn |
NCT04021927 -
Development of a Neonatal Jaundice Treatment Accelerator by Redirection of Unused Light During Phototherapy
|
N/A | |
Completed |
NCT00966719 -
Breastfeeding Support Intervention in Jaundiced Infants
|
N/A | |
Completed |
NCT02033096 -
Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
|
||
Terminated |
NCT01514058 -
A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction
|
N/A | |
Completed |
NCT01203410 -
Prediction of Jaundice in Term Infants
|
||
Not yet recruiting |
NCT06232174 -
Value of Transcutaneous Bilirubin Devices
|
||
Completed |
NCT01356030 -
Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer
|
N/A | |
Not yet recruiting |
NCT06276738 -
The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease
|
||
Completed |
NCT02787512 -
Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer
|
N/A | |
Completed |
NCT02991339 -
The Effects of Dexamethasone Administration on Jaundice Following Liver Resection
|
Phase 2/Phase 3 | |
Withdrawn |
NCT00240123 -
Effect of Benadryl Sedation During ERCP or EUS
|
Phase 1 | |
Completed |
NCT02926131 -
A Study to Evaluate a New Jaundice Stick Test
|
||
Completed |
NCT01499537 -
Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct
|
N/A | |
Active, not recruiting |
NCT02376907 -
Biliary Drainage in Patients With Duodenal Metal Stent
|
N/A | |
Terminated |
NCT01887041 -
Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer
|
Phase 4 | |
Recruiting |
NCT06173947 -
SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
|
||
Active, not recruiting |
NCT04271176 -
Jaundice as Initial Presentation of Liver Hydatidosis (ICTEHIDA)
|
||
Completed |
NCT01976936 -
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
|
Phase 2 |